Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label monthly intramuscular glatiramer acetate depot in primary progressive multiple sclerosis
MOH_2017-09-10_000795Phase 2Completed
- Sponsor
- Mapi Pharma
- Start
- Apr 2017
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of glatiramer acetate in primary progressive multiple sclerosis (PPMS) (2 arms), sponsored by Mapi Pharma. Started Apr 2017; status: completed.
02
Drugs
glatiramer acetate
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on MOH_2017-09-10_000795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-09-10_000795.